IONS Form 4: Eric Swayze Reports 11,130-Share Sale Under 10b5-1
Rhea-AI Filing Summary
Eric Swayze, EVP Research at Ionis Pharmaceuticals (IONS), reported insider sales on 09/02/2025. He sold 10,000 shares at a weighted average price of $49.22 and 1,130 shares at a weighted average price of $53.6829 under a Rule 10b5-1 trading plan adopted August 14, 2024. After these transactions the filing shows beneficial ownership figures of 38,432 and 37,302 shares respectively, and an indirect holding of 184 shares held by his son. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Positive
- Sales executed under a Rule 10b5-1 trading plan, indicating pre-planned transactions and potential affirmative defense to insider trading claims
- Weighted average prices and price ranges disclosed, with an undertaking to provide detailed per-price breakdowns on request
- Timely filing and signature by attorney-in-fact recorded on 09/04/2025, supporting regulatory disclosure compliance
Negative
- Insider sold 11,130 shares in total (10,000 and 1,130), reducing reported direct beneficial ownership levels
- Form does not state percent ownership or prior holdings on this filing, limiting context on the materiality of the sales
Insights
TL;DR: Routine, pre-planned insider sales; limited immediate signal about company fundamentals.
The reported sales total 11,130 shares executed under a documented 10b5-1 plan, which typically indicates pre-scheduled transactions rather than opportunistic trades. The weighted average prices reported provide transparency about execution ranges. The remaining direct beneficial ownership levels reported on the form should be compared to prior filings to assess change in percent ownership, which is not provided here. No derivatives or other compensatory transactions are disclosed on this Form 4.
TL;DR: Use of a 10b5-1 plan and timely Form 4 filing align with standard governance and disclosure practices.
The filing documents that the reporting person adopted a Rule 10b5-1 trading plan on August 14, 2024 and that sales occurred on September 2, 2025, consistent with an affirmative defense to insider trading claims. The disclosure includes weighted average price ranges and an undertaking to provide further breakdowns upon request, which supports transparency. The signature by attorney-in-fact is noted and the relationship to the issuer is clearly stated as EVP Research.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,000 | $49.22 | $492K |
| Sale | Common Stock | 1,130 | $53.6829 | $61K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.14 to $49.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $53.72 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
